Bone Therapeutics, the cell therapy company and Catalent Pharma Solutions, provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies have announced the signing of share purchase and supply agreements. The agreements will streamline and economise the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus its strategy on the development of products from its differentiated MSC (Mesenchymal Stromal Cell) platform of cell and gene therapeutic targets for orthopaedics and other indications.
Under the terms of the agreement, Catalent will acquire Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), for gross proceeds of EUR 12 million.
Bone Therapeutics and Catalent additionally signed an associated supply agreement. Under this agreement, the acquired manufacturing entity will continue to service the production of ALLOB for Bone Therapeutics and its partners. This will grant Bone Therapeutics access to Catalent’s global network of clinical and commercial manufacturing facilities, and will ensure ongoing optimisation, sustainability and a global reach for the production of ALLOB, as the product heads through clinical development and anticipated commercialisation.
“This agreement with Catalent is an important strategic step for Bone Therapeutics and is the result of our continuous effort to optimise our operations,” said Miguel Forte, CEO, Bone Therapeutics. “The integration of our manufacturing subsidiary into Catalent, one of the premier contract manufacturers in the cell therapy space, significantly increases our operational flexibility. It enables Bone Therapeutics to maximise the efficient use of our manufacturing assets by combining the manufacturing facility and specialist operators with Catalent’s global network of clinical and commercial manufacturing facilities and safeguards the employment level at the manufacturing facility. This will ensure the most efficient ongoing global production of ALLOB. It also allows us to further focus on our core activity: developing innovative cell-based treatments for conditions with high unmet medical needs.”
Image credit: Adam Niescioruk
